



GB/03/3747

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 10 OCT 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

P. Mahoney
26 September 2003

An Executive Agency of the Department of Trade and Industry


BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(No 16)



02SEP02 E744991-1 010100
P01/7700 0.00-0220257.0



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

CG/P/202/GBA

2. Patent application number

(The Patent Office will fill in this part)

0220257.0

31 AUG 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

The Secretary of State for Defence
DSTL
Porton Down
Salisbury
Wiltshire
SP4 0JQ
GB

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

6997670005 *TA*

4. Title of the invention

Vaccine

5. Name of your agent (if you have one)

Carol P. Greaves et al.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Greaves Brewster
24A Woodborough Road
Winscombe
North Somerset
BS25 1AD
GB

Patents ADP number (if you know it)

8285579001 *TA*

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Yes

Patents Form 1/77

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	16
Claim(s)	3
Abstract	1
Drawing(s)	2 + 2 <i>1/2</i>

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)


One *1/2*

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature



Date 30/8/02

12. Name and daytime telephone number of person to contact in the United Kingdom

Carol Greaves 01934 844419

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

DUPLICATE

1

VACCINE

The present invention relates to antibodies, which are administered to a human or animal prophylactically or as a therapy.

In particular, the present invention relates to antibodies, which act synergistically when administered prophylactically and when administered as a therapy.

10

The present invention also relates to novel vaccines and the protection and treatment against the organism *Yersinia pestis*. Such vaccines are capable of offering protection against bubonic and pneumonic plague.

15

Yersinia pestis, the causative agent of plague, has accounted for the deaths of millions of people throughout recorded history. The second pandemic (The Black Death) is thought to have killed an estimated 17 million to 28 million Europeans between the 14th and 17th centuries. The third pandemic, believed to have started in the Yunan Province of China in the 1850s, has lead to the worldwide spread of plague, which is now endemic to several regions including Africa, India and the South Western states of the USA (Perry, R. D. et al. 1997. Clinical Microbiology Reviews 10:35-66). Despite the current low incidence of plague, the bacterium resides in natural animal reservoirs and regular, though relatively small outbreaks of plague occur (Duplantier, J. M. et al. 2001. Bulletin De La Societe De Pathologie Exotique 94:119-122; Migliani, R. et al. 2001. Bulletin De La Societe De Pathologie Exotique 94:115-118; Ratsitorahina, M. et al. 2000. Lancet 355:111-113).

Improvements in transport links between endemic areas and large population centres bring with it the potential for large-scale plague outbreaks, highlighted by the recent outbreak in India (Shivaji, S. et al. 2000. Fems Microbiology Letters 189:247-

35

252). There is therefore a need for effective disease surveillance to reduce the risk of plague transmission to new areas and subsequent outbreaks of disease.

- 5 Vaccination is recommended for research scientists and other professionals who come into contact with the bacterium, but fast-acting treatments are also required for individuals exposed to *Y. pestis* in endemic areas, or through their work. In addition, after a major outbreak there would be a need to
- 10 protect healthcare workers and first-responders.

At present protection against plague can be mediated through vaccination or antibiotic treatment. Antibiotics, including streptomycin and tetracycline, are used both to treat plague

15 victims and as prophylaxis to control the spread of the disease (Perry, R. D. et al. 1997. Clinical Microbiology Reviews 10:35-66). The incidence of antibiotic resistance in *Y. pestis* is low but recent plague isolates in Madagascar have been found to have multiple drug resistance, conferred by a transferable plasmid

20 (Guiyoule, A. G. et al. 2001. Emerging Infectious Diseases 7:43-48; Guiyoule, A. et al. 1997. Journal of Clinical Microbiology 35:2826-2833). Existing plague vaccines include killed whole-cell preparations and efforts to develop new vaccines are in progress (Williamson, E. D. 2001. Journal of Applied

25 Microbiology 91:606-608).

Problems associated with whole-cell vaccines include relatively low levels of protection, adverse side-effects, slow time-to-immunity, and a need for regular booster immunisations (Russell,

30 P et al. 1995. Vaccine 13:1551-1556). Although whole cell vaccines are thought to be effective against the most common form of plague (bubonic plague), that develops following a bite from an infected insect, their efficacy against pneumonic plague has been questioned.

Next-generation plague sub-unit vaccines are being developed, based on the recombinant F1-antigen (F1) and low calcium response V-antigen (LcrV) proteins, derived from *Y. pestis*. Immunisation with either protein provides protection against pneumonic or bubonic disease in animal models of infection (Heath, D. G. et al. 1998. Vaccine **16**:1131-1137; Leary, S. E. C. et al. 1995. Infection and Immunity **63**:2854-2858; Williamson, E. D. 2001. Journal of Applied Microbiology **91**:606-608) but greater than additive protection is achieved when F1 and LcrV are combined, with protection against up to 10⁹ median lethal doses (MLD) of *Y. pestis* reported (Williamson, E. D. et al. 1995. Fems Immunology and Medical Microbiology **12**:223-230). Such vaccines must be administered prior to exposure, and multiple doses are required. Although strategies to reduce the time to immunity and the number of vaccine doses have shown promise (Williamson, E. D. et al. 2000. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine **19**:566-571), it is unlikely that vaccination will provide post-exposure protection against disease.

20

There is therefore a need for fast-acting anti-plague treatments to provide rapid therapy, particularly in the event that drug resistant strains of *Y. pestis* are involved.

Previously, F1-04-A-G1, a mouse monoclonal antibody raised against F1 was shown to protect mice in models for bubonic and pneumonic plague (Anderson, G. W. et al. 1997. American Journal of Tropical Medicine and Hygiene **56**:471-473). Also, preliminary studies showed that an LcrV-specific monoclonal antibody (Mab 7.3) protected mice in a bubonic plague model (Hill, J. et al. 1997. Infection and Immunity **65**:4476-4482).

Although antisera have been used to treat a range of diseases caused by other pathogens (Keller M. A. et al. 2000. Clin. Microbiol. Rev. **2000** **13**:602-14), neither antisera nor monoclonal antibodies have been previously proposed as a treatment for

plague. The applicants have found however, that antibody therapy is effective in treating plague infections, and that combinations of antibodies can operate synergistically in providing protection against infection.

5

According to the present invention there is provided the use of (i) an antibody specific for *Yersinia pestis* F1-antigen, or a binding fragment thereof, or (ii) an antibody specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection by *Yersinia pestis*.

As used herein the term "binding fragment" refers to fragments of antibodies such as F(ab) and F(ab') fragments, or single chain antibodies, which bind to the target antigen.

In particular, the medicament will comprise a combination of (i) and (ii) is used. Preferably the combination comprises at least one antibody specific for *Yersinia pestis* F1-antigen, and at least one antibody specific for *Yersinia pestis* V-antigen.

If desired, more than one antibody specific for different epitopes within the F1-antigen and/or V-antigen, can be employed.

25

Suitably the antibodies used are monoclonal antibodies or binding fragments thereof, but in particular are monoclonal antibodies.

In particular, the antibody specific for *Yersinia pestis* V-antigen or binding fragment thereof specifically binds an epitope of the V-antigen found between amino acids 1 and 275 and preferably an epitope found between amino acids 135-275 of the sequence of the V-antigen as shown for instance in WO 96/28551. Passive transfer of LcrV-specific polyclonal antiserum protected mice against plague and that protective epitopes were assigned

to region 168-275 (Motin, V. L. et al. 1994.. Infection and Immunity 62:4192-4201). Similarly, Mab 7.3 used in the present application has been mapped to bind to a conformational epitope between aa 135-275 of LcrV (Hill, J. et al. 1997. Infection and Immunity 65:4476-4482). Therefore, this central region of LcrV appears to be a good target for antibodies useful in the present invention.

Suitably the medicament is for administration up to about 48 hours post-infection, although longer periods may be envisaged if the dosage is increased sufficiently.

A number of strategies can be used to increase the clinical acceptability of the antibodies or binding fragments (Casadevall, A. 1999. Clinical Immunology 93:5-15). For example, the specificity of animal antibodies can be transferred to a human antibody framework, a process termed "humanisation" (Taylor, G. et al. 1991. Lancet 337:1411-1412; Winter, G. et al. 1993. Trends in Pharmacological Sciences 14:139-143) or animal antibodies can be chemically treated to improve their therapeutic properties (Mayers, C. N. et al. 2001. Reviews in Medical Microbiology 12:29-37). Alternatively, antibodies can be generated from naïve human single chain antibody libraries (de Haard, H. J. et al. 1999. Journal of Biological Chemistry 274:18218-18230; Knappik, A. et al. 2000. Journal of Molecular Biology 296:57-86; Nissim, A. et al. 1994. Embo Journal 13:692-698) or from immunised transgenic animals that express a human antibody repertoire (Neuberger, M. et al. 1997. Nature 386:25-26).

In a particularly preferred embodiment, the antibodies or binding fragments thereof used are "humanised" by humanisation as described above, or are fully human antibodies as a result of generation from human libraries, or transgenic animals, also as described above.

The applicants have demonstrated that monoclonal antibodies specific for *Y. pestis* surface proteins can be used as a therapy for the treatment of plague. Mabs 7.3 and F1-04-A-G1 were more effective as a therapy when combined than as a single treatment, providing significant protection when administered up to 2 days after s.c. *Y. pestis* challenge.

In a further aspect, the invention provides a method of treating a human or animal suffering from the effects of infection with *Yersinia pestis*, said method comprising administering to the human or animal, a therapeutically effective amount of (i) an antibody specific for *Yersinia pestis* F1-antigen, or a binding fragment thereof, or (ii) an antibody specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), and in particular a combination of (i) and (ii) as described above.

Suitably the treatment is administered within 48 hours, and preferably within 24 hours of exposure to the infective *Yersinia pestis* organism.

The antibodies are suitably administered in the form of a pharmaceutical composition, which suitably includes a pharmaceutically acceptable carrier. Suitable carriers include solid or liquid carriers, such as saline, as are known in the art.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous,

subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing.

The compositions of the invention may be obtained by
5 conventional procedures using conventional pharmaceutical excipients, well known in the art.

For example, the pharmaceutical compositions may be in the form
10 of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents.

15 Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active antibody composition either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or
20 hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry
25 (Corwin Hansch; Chairman of Editorial Board, Pergamon Press 1990).

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily
30 vary depending upon the host treated and the particular route of administration. Dosage unit forms will generally contain about 1 mg to about 2g of an active ingredient.

The size of the dose for therapeutic or prophylactic purposes of
35 the compositions of the invention will vary according to the nature and severity of the conditions, the age and sex of the

animal or patient and the route of administration, according to well known principles of medicine. Generally however, for therapeutic or prophylactic purposes, it will generally be administered so that a periodic dose in the range, for example,
5 0.5 mg to 75 mg per kg body weight is received.

Thus in yet a further aspect, the invention provides a pharmaceutical composition comprising an antibody specific for the *Yersinia pestis* V-antigen or a binding fragment thereof, and
10 an antibody specific for the *Yersinia pestis* F1-antigen or a binding fragment thereof.

In particular the composition comprises an antibody specific for the *Yersinia pestis* V-antigen or a binding fragment thereof, and
15 an antibody specific for the *Yersinia pestis* F1-antigen or a binding fragment thereof. Preferably these are antibodies, and most preferably monoclonal antibodies, which may be humanised or fully human. Preferred antibodies for inclusion in the composition are as described above.

20 The applicants have also found that the combination of antibodies protected mice against 10^5 MLD s.c. challenge when administered as a pre-treatment. The data presented here mirrors observations that LcrV and F1 provide greater than
25 additive protection when included in plague sub-unit vaccines (Williamson, E. D. et al. 1995. *Fems Immunology and Medical Microbiology* 12:223-230). Vaccine-mediated protection correlates with high specific polyclonal antibody titres to F1 and LcrV (Williamson, E. D. et al. 1999. *Clinical and*
30 *Experimental Immunology* 116:107-114), which agrees with the present observation that the degree of protection was found to be proportional to the amount of protective antibody administered (Table 1 hereinafter).

35 Thus the pharmaceutical compositions of the invention may be used as a prophylactic vaccine for passive immunisation for the

protection of a human or animal against infection by *Yersinia pestis*, and these vaccines form a further aspect of the invention.

- 5 Yet a further aspect comprises a method of immunising against infection by *Yersinia pestis* comprising administering a vaccine as described above.

10 In a further aspect, the invention provides the use of a combination of an antibody specific for *Yersinia pestis* Fl-antigen, or a binding fragment thereof, and an antibody specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, in the production of a medicament for the passive immunisation of a human or animal against infection by *Yersinia pestis*.

- 15 Preferred antibody combinations are as described above in relation to the use in therapy.

20 LcrV has a key role in type III secretion (TTS) by the *Yersinia* spp., a process that allows the injection of a set of effector proteins directly into the cytosol of eukaryotic target cells upon intimate contact (Cornelis, G. R. 1998. *Journal of Bacteriology* **180**:5495-5504; Hueck, C. J. 1998. *Microbiology and Molecular Biology Reviews* **62**:379-433; Rosqvist, R. et al. 1991. *Infection and Immunity* **59**:4562-4569; Rosqvist, R. et al. 1994. *Embo Journal* **13**:964-972). The effector proteins (termed Yops) have a range of function that promote the killing of phagocytic host cells. Protective polyclonal antisera inhibited *Yersinia* TTS in HELA cell cytotoxicity experiments and LcrV was detected
30 at the bacterial surface prior to contact with eukaryotic cells by confocal microscopy analysis (Pettersson, J. A. et al. 1999. *Molecular Microbiology* **32**:961-976). A similar study showed that Mab 7.3, but not other non-protective Mabs, protected J774 macrophage-like cells against *Yersinia*-mediated killing (Weeks, S. et al. 2002. *Microbial Pathogenesis* **32**:227-237). Antiserum
35 raised against the LcrV homologue of *Pseudomonas aeruginosa*

(PcrV) protected mice in a lung infection model and antiserum inhibited TTS-mediated cytotoxicity of J774 cells (Frank, D. W. et al. 2002. *Journal of Infectious Diseases* 186:64-73; Sawa, T. et al. 1999. *Nature Medicine* 5:392-398), and anti-PcrV F(ab')₂ fragment provided therapeutic protection in a model for disease (Shime, N. et al. 2001. *Journal of Immunology* 167:5880-5886).

However, others did not show a correlation between protective LcrV-specific polyclonal antiserum in cytotoxicity assays (Fields, K. A. et al. 1999. Virulence role of V antigen of *Yersinia pestis* at the bacterial surface. *Infection and Immunity* 67:5395-5408). LcrV is also reported to have immunomodulatory properties (Motin, V. L. et al. 1997. *Transplantation* 63:1040-1042; Nakajima, R. et al. 1995. *Infection and Immunity* 63:3021-3029; Sing, A. et al. 2002. *Journal of Immunology* 168:1315-1321; Welkos, S. et al. 1998. *Microbial Pathogenesis* 24:185-196), so it remains a possibility that antibodies inhibit both TTS as well as the anti-inflammatory properties of *Y. pestis*, by blocking the interaction of secreted LcrV with an unidentified eukaryotic receptor.

F1 is expressed optimally at 37°C and is thought to inhibit phagocytosis through the formation of a capsule-like structure on the bacterial surface, and is an effective plague vaccine (Andrews, G. P. et al. 1996. *Infection and Immunity* 64:2180-2187; Du, Y. D. et al. 2002. *Infection and Immunity* 70:1453-1460; Heath, D. G. et al. 1998. *Vaccine* 16:1131-1137; Titball, R. W. et al. 1997. *Infection and Immunity* 65:1926-1930). A recent report showed that an isogenic F1 plague mutant has impaired resistance to phagocytosis by J774 cells (Du, Y. D. et al. 2002. *Infection and Immunity* 70:1453-1460). Also, a virulence plasmid cured strain, deficient for TTS, was less resistant to phagocytosis and an additive effect was seen with the double mutant (F1-negative, plasmid cured strain). It was proposed that the TTS system and F1 capsule synthesis contribute in different ways to maintain the extracellular lifestyle of *Y.*

pestis (Du, Y. D. et al. 2002. *Infection and Immunity* 70:1453-1460). By using the invention, both the TTS system and the F1 capsule of the organism are targeted, which might explain the high level of protection observed in the following examples.

- 5 The present invention will now be described only by way of examples in which reference shall be made to the following Figures in which:-

Figure 1 is a graph showing therapeutic Mab 7.3 treatment of mice challenged with *Y. pestis* via the s.c. (A) and aerosol (B) infection routes. Mice received 35 µg of Mab 7.3 in PBS by i.p. injection 4 hours before or up to 72 hours after challenge, as indicated. Deaths were recorded over a 14 day period. Delayed time to death observed in animals treated with Mab 7.3 at 72 hours (A) and 60 h (B) were statistically significant ($P < 0.05$) by Student's T-test analysis compared with untreated control groups

Figure 2 is a graph showing that Mab 7.3 and F1-04-AG-1 display synergy when administered post-infection. Mice were challenged s.c. with 91 MLD *Y. pestis* and treated 48 hours after plague challenge with Mab 7.3 (35 µg), F1-04-A-G1 (100 µg) or both antibodies. Deaths were recorded over a 14 day period.

25 EXAMPLE 1

Preparation of Antibodies

Mab 7.3 and F1-04-A-G1 were purified by ammonium sulphate precipitation from hybridoma supernatants. An equal volume of saturated ammonium sulphate solution was added slowly to tissue culture supernatants, followed by overnight stirring at 4°C, then centrifugation at 3,000 g for 30 min. The pellets were drained and resuspended in PBS (GIBCO, UK) in 0.1 volumes of the original volume, then dialysed against three changes of PBS. Disposable Econopak columns (BioRad, UK) were packed with protein-G-sepharose beads (Sigma, UK) and antibody solution was passed through the column. The beads were washed with PBS, then

antibody was eluted with 50 mM glycine (pH 3) and stored in fractions containing 150 µl Tris HCl (pH 9.1) per 3ml of eluate. Protein fractions were analysed by SDS-PAGE on 10-15% Phastgels (Pharmacia, UK) and fractions containing antibody were dialysed against three changes of PBS. Antibody concentration was determined by BCA assay (Perbio, UK) with a BSA standard as recommended by the manufacturers. Antibody purity was assessed by SDS-PAGE analysis.

10 Example 2

Biological Testing

Antibodies were tested in murine models of bubonic and pneumonic plague. Six to eight week old Balb/c mice were used (Charles River Limited, UK). Animal Experiments were performed in accordance with UK legislation relating to animal experimentation (Animals (Scientific Procedures) Act 1986).

Mice received antibody by intraperitoneal (i.p.) injection in 100 µl of PBS, prior to or after infection as indicated in Tables 1 to 3 hereinafter. *Y. pestis* strain GB, a fully virulent human isolate, with an estimated median lethal dose (MLD) of 1 colony forming unit via the s.c. route (Russell, P et al. 1995. Vaccine 13:1551-1556) was used in all challenge experiments. In the bubonic plague model mice received 10 to 10⁵ MLD resuspended in 100 µl PBS, by subcutaneous (s.c.) injection. In the pneumonic plague model mice were exposed to approximately 100 MLD of airborne bacteria, as described previously (Williamson, E. D. et al. 1997 Vaccine 15:1079-1084). Animals were checked at least twice daily and deaths recorded over a 14 day period.

Results

Mab 7.3 protection data.

Mice were treated with purified Mab 7.3 24 hours prior to challenge with 10 MLD or 100 MLD of *Y. pestis*. As little as 3.5

µg of antibody protected mice and extended the mean time to death (TTD) of animals that died (Table 1).

TABLE 1. Dose-dependent protection against bubonic plague with purified Mab 7.3.

Mab 7.3 (µg) *	MLD [†]	Survivors/group	TTD ± SEM [§]
35	10	5/6	4.0
10.5	10	5/6	6.0
3.5	10	0/6	8.2±1.1
0.7	10	1/6	4.8±0.5
none	10	0/6	4.8±0.3
35	100	3/6	6.3±0.8
10.5	100	3/6	3.8±2.7
3.5	100	1/6	6.4±1.5
0.7	100	0/6	5.2±0.4
none	100	0/6	4.1±0.3

* Mab 7.3 administered i.p. 24 hours before challenge

† *Y. pestis* administered by s.c. injection in 100 µl PBS

§ Student's T-test: $p < 0.05$ compared with PBS control groups receiving the equivalent challenge.

Greater survival was noted in groups given 10.5 µg or 35 µg, compared with those that received 3.5 µg and 0.7 µg of Mab 7.3.

The degree of protection was less in animals that received 100 MLD than those injected with 10 MLD (50% and 83% survivors respectively). Therefore, protection against plague was directly proportional to the amount of antibody administered and inversely proportional to the challenge dose.

20

Five mice received 50 µg Mab 7.3 in 100 µl PBS by intraperitoneal (i.p.) injection and serum levels were determined at different times by anti-LcrV-specific ELISA as described previously (Hill, J. et al. 1997. Infection and

Immunity 65:4476-4482). The serum half-life of Mab 7.3 was

25

determined as 5.6 days. The serum antibody level 28 days after dosing was calculated as 2 µg, and five immunised animals were challenged with 18 MLD *Y. pestis* on day 28-post antibody treatment. All Mab 7.3-treated animals survived, whereas 6 of 6 untreated mice died. This experiment demonstrated the potential for a single dose of antibody as a long-lasting prophylactic.

Mab 7.3 was administered -4 hours, +24 hours, +48 hours, or +96 hours relative to s.c. *Y. pestis* challenge. Protection was observed when antibody was given up to 48 hours post-infection (Fig. 1A). Also, a delayed time to death was observed in the +96 hours treatment group. One of +96 hours treatment group had died prior to antibody administration and the remainder displayed signs of plague indistinguishable from untreated control animals, suggesting that even when symptoms of plague are apparent antibody therapy can delay death. Mice were treated with Mab 7.3 at -4 hours, +24 hours, +48 hours or +60 hours relative to aerosol infection (Fig. 1B). Protection was seen in groups that received antibody 24 hours and 48 hours after challenge. All mice treated at +60 hours died, but a statistically significant delay in the TTD was observed, compared with untreated animals.

Combined F1-04-A-G1 and Mab 7.3 treatment.

F1-04-A-G1, administered singly or in combination with Mab 7.3 prior to aerosol challenge, protected mice against plague (Table 2).

TABLE 2. F1-04-A-G1 and Mab 7.3 protect against aerosol plague challenge.

Antibody treatment *	Aerosol challenge dose (MLD)	Survivors per group †
PBS	100	0/10
F1-04-A-G1	100	9/10
Mab 7.3	100	10/10
F1-04-A-G1 + Mab 7.3	100	9/10

5 * 35 µg of Mab 7.3 and/or 100 µg of F1-04-A-G administered by i.p. injection in 100 µg PBS, 4 hours prior to challenge.

† Deaths recorded over a 14 day period

This confirmed the prophylactic properties of F1-04-A-G1 in the
 10 pneumonic plague model (Anderson, G. W. et al. 1997. American Journal of Tropical Medicine and Hygiene 56:471-473). Mab 7.3 was less effective as a treatment against s.c. *Y. pestis* challenge than aerosol challenge (Fig. 1), therefore the bubonic plague model chosen for further co-administration studies to
 15 test for antibody synergy.

First, antibodies were tested as a pre-treatment against challenge with 50 to 10⁵ MLD of *Y. pestis* GB (Table 3).

20 TABLE 3. Enhanced protection with F1-04-A-G1 and Mab 7.3 as a pre-treatment.

Antibody treatment*	<i>Y. pestis</i> challenge (MLD) †	Survivors per group ^s
untreated	50	0/6
F1-04-A-G1 + Mab 7.3	10 ²	6/6
F1-04-A-G1 + Mab 7.3	10 ³	6/6
F1-04-A-G1 + Mab 7.3	10 ⁴	5/6
F1-04-A-G1 + Mab 7.3	10 ⁵	6/6

* mice were immunised i.p.. with 35 µg Mab 7.3 and 100 µg F1-04-A-G1 in PBS.

† s.c plague challenge 4 h after antibody administration
S

5

Surprisingly, protection was observed at all challenge doses; breakthrough was expected at challenge doses greater than 100 MLD (see Table 1 and Anderson, G. W. et al. 1997. American Journal of Tropical Medicine and Hygiene 56:471-473). Next the

10 combined antibody treatment was tested as a plague therapy. Mice that received the antibody cocktail 48 hours after challenge were protected better than animals that received single antibody therapy (Fig. 2). The data indicates that Mab 7.3 and F1-04-A-G1 act synergistically as a pre-treatment and as a therapeutic
15 in our plague models.

CLAIMS

1. The use of (i) an antibody specific for *Yersinia pestis* F1-antigen, or a binding fragment thereof, or (ii) an antibody
5 specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection by *Yersinia pestis*.
2. The use according to claim 1 wherein a combination of (i)
10 and (ii) is used.
3. The use according to claim 2 wherein the said combination comprises an antibody specific for *Yersinia pestis* F1-antigen, and an antibody specific for *Yersinia pestis* V-antigen.
15
4. The use according to any one of the preceding claims wherein the antibodies are monoclonal antibodies.
5. The use according to any one of the preceding claims
20 wherein the medicament is for administration up to about 48 hours post-infection.
6. The use according to any one of the preceding claims wherein the antibody specific for *Yersinia pestis* V-antigen or
25 binding fragment thereof specifically binds an epitope of the V-antigen found between amino acids 135-275 of the sequence of the V-antigen.
7. The use according to any one of the preceding claims
30 wherein the antibodies or binding fragments thereof, are humanised.
8. A method of treating a human or animal suffering from the effects of infection with *Yersinia pestis*, said method
35 comprising administering to the human or animal, a therapeutically effective amount of (i) an antibody specific for

Yersinia pestis F1-antigen, or a binding fragment thereof, or
(ii) an antibody specific for *Yersinia pestis* V-antigen, or a
binding fragment thereof, or a combination of (i) and (ii).

5 9. A method according to claim 8 wherein the method comprises
administering a combination of (i) and (ii).

10 10. A pharmaceutical composition comprising an antibody
specific for the *Yersinia pestis* V-antigen or a binding fragment
thereof, and an antibody specific for the *Yersinia pestis* F1-
antigen or a binding fragment thereof.

11. A pharmaceutical composition according to claim 10 which
comprises an antibody specific for the *Yersinia pestis* V-antigen
15 or a binding fragment thereof, and an antibody specific for the
Yersinia pestis F1-antigen or a binding fragment thereof.

12. A pharmaceutical composition according to claim 10 or claim
11 wherein the antibodies are monoclonal antibodies.

20

13. A pharmaceutical composition according to any one of claims
10 to 12 wherein the antibody specific for *Yersinia pestis* V-
antigen or binding fragment thereof specifically binds an
epitope of the V-antigen found between amino acids 135-275 of
25 the sequence of the V-antigen.

14. A pharmaceutical composition according to any one of claims
10 to 13 wherein the antibodies or binding fragments thereof,
are humanised or are fully human.

30

15. A prophylactic vaccine for protection of a human or animal
against infection by *Yersinia pestis*, said vaccine comprising a
composition according to any one of claims 10 to 14.

35 16. A method of immunising against infection by *Yersinia pestis*
comprising administering a vaccine according to claim 15.

17. The use of a combination of an antibody specific for *Yersinia pestis* F1-antigen, or a binding fragment thereof, and an antibody specific for *Yersinia pestis* V-antigen, or a binding
5 fragment thereof, in the production of a medicament for the passive immunisation of a human or animal against infection by *Yersinia pestis*.

18. A use, a method or a composition substantially as
10 hereinbefore described with reference to the accompanying figures.

ABSTRACT

The use of (i) an antibody specific for *Yersinia pestis* F1-antigen, or a binding fragment thereof, or (ii) an antibody
5 specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection by *Yersinia pestis*.

It has been found that such treatments are effective therapies
10 for *Yersinia pestis* infection. In addition, the combination produces a synergistic effect when used prophylactically.

FIGURE 1




A. Injected challenge (50 MLD)**B. Aerosol challenge (100 MLD)**

FIGURE 2



PCT Application

GB0303747



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.